The effect of Momordica charantia capsule preparation on glycemic control in Type 2 Diabetes Mellitus needs further studies

Dans, Antonio; Villarruz, Maria Vanessa C.; Jimeno, Cecilia; Javelosa, Mark Anthony U.; Chua, Joel; Bautista, Rhida; Velez, Gwyneth Giselle B.

doi:10.1016/j.jclinepi.2006.07.009

Cited by 166 publications

(135 citation statements)

References 13 publications

(8 reference statements)

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Hussain, 2007) and another two papers provided findings of Nagao et al, 2009). The rest of the seven papers were focussed on 7 diffent plant-based preparations for T2DM (A.M. Dans et al, 2007;H.F. Huseini et al, 2009;V.T.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…Recruitment of patients was limited to the centres of the studies. Of the 15 included randomised trials, five trials described the methods of randomisation (P. Crawford, 2009;A.M. Dans et al, 2007;H.F.…”

Section: Risks Of Biasmentioning

confidence: 99%

“…Vuksan et al, 2008). Among them, three used simple randomisation methods (random number generator, table and computer generated sequence) (A.M. Dans et al, 2007; T. Mackenzie et al, 2007;V. Vuksan et al, 2008), one used block randomisation technique (P. Crawford, 2009) and another used a balanced randomisation technique (H.F. Huseini et al, 2006).…”

Section: Risks Of Biasmentioning

confidence: 99%

“…Vuksan et al, 2008), one used block randomisation technique (P. Crawford, 2009) and another used a balanced randomisation technique (H.F. Huseini et al, 2006). Only three trials reported generation of allocation concealment (P. Crawford, 2009;A.M. Dans et al, 2007;H.F.…”

Section: Risks Of Biasmentioning

confidence: 99%

“…Blevins et al, 2007;P. Crawford, 2009;A.M. Dans et al, 2007; T. Mackenzie et al, 2007; V. Vuksan et al, 2008).…”

Section: Risks Of Biasmentioning

confidence: 99%

See 4 more Smart Citations

A Review of Clinical Trials in Emerging Botanical Interventions for Type 2 Diabetes Mellitus

Ooi¹,

Loke²,

Hamid³

2011

Topics in the Prevention, Treatment and Complications of Type 2 Diabetes

View full text Add to dashboard Cite

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Section: Risks Of Biasmentioning

confidence: 99%

Section: Risks Of Biasmentioning

confidence: 99%

Section: Risks Of Biasmentioning

confidence: 99%

“…Blevins et al, 2007;P. Crawford, 2009;A.M. Dans et al, 2007; T. Mackenzie et al, 2007; V. Vuksan et al, 2008).…”

Section: Risks Of Biasmentioning

confidence: 99%

See 3 more Smart Citations

A Review of Clinical Trials in Emerging Botanical Interventions for Type 2 Diabetes Mellitus

Ooi¹,

Loke²,

Hamid³

2011

Topics in the Prevention, Treatment and Complications of Type 2 Diabetes

View full text Add to dashboard Cite

Momordica charantia for type 2 diabetes mellitus

Ooi

Yassin

Hamid

2010

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Momordica charantia (bitter gourd) is not only a nutritious vegetable but it is also used in traditional medical practices to treat type 2 diabetes mellitus. Experimental studies with animals and humans suggested that the vegetable has a possible role in glycaemic control. To assess the effects of mormodica charantia for type 2 diabetes mellitus. Several electronic databases were searched, among these were The Cochrane Library (Issue 1, 2012), MEDLINE, EMBASE, CINAHL, SIGLE and LILACS (all up to February 2012), combined with handsearches. No language restriction was used. We included randomised controlled trials (RCTs) that compared momordica charantia with placebo or a control intervention, with or without pharmacological or non-pharmacological interventions. Two authors independently extracted data. Risk of bias of the trials was evaluated using the parameters of randomisation, allocation concealment, blinding, completeness of outcome data, selective reporting and other potential sources of bias. A meta-analysis was not performed given the quality of data and the variability of preparations of momordica charantia used in the interventions (no similar preparation was tested twice). Four randomised controlled trials with up to three months duration and investigating 479 participants met the inclusion criteria. Risk of bias of these trials (only two studies were published as a full peer-reviewed publication) was generally high. Two RCTs compared the effects of preparations from different parts of the momordica charantia plant with placebo on glycaemic control in type 2 diabetes mellitus. There was no statistically significant difference in the glycaemic control with momordica charantia preparations compared to placebo. When momordica charantia was compared to metformin or glibenclamide, there was also no significant change in reliable parameters of glycaemic control. No serious adverse effects were reported in any trial. No trial investigated death from any cause, morbidity, health-related quality of life or costs. There is insufficient evidence on the effects of momordica charantia for type 2 diabetes mellitus. Further studies are therefore required to address the issues of standardization and the quality control of preparations. For medical nutritional therapy, further observational trials evaluating the effects of momordica charantia are needed before RCTs are established to guide any recommendations in clinical practice.

show abstract